Discussion
Apollo Therapeutics plans to launch a Phase 2 trial in the first half of 2027 to test whether its experimental vaccine APL-10456 can prevent disease flares in people with chronic obstructive pulmonary disease (COPD). According to a company press release, Apollo has completed enrollment and dosing in…